Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Rescue Emetic Therapy for Children Having Elective Surgery (RETCHES)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by Children's Hospital of Pittsburgh.
Recruitment status was  Recruiting
Information provided by:
Children's Hospital of Pittsburgh Identifier:
First received: February 10, 2010
Last updated: June 21, 2011
Last verified: September 2009

To compare ondansetron, metoclopramide, diphenhydramine, and placebo in order to determine which anti-emetic is most efficacious as a "rescue therapy" for pediatric patients ages 3-18 who have post-operative vomiting after a standardized prophylactic regimen of ondansetron and dexamethasone. We hypothesize that anti-emetics with a different mechanism of action than the prophylactic regimen will be the most effective "rescue therapy" in children having surgery in an ambulatory surgery center.

  1. Problem: Despite commonly-used anti-emetics for prophylaxis, some children still go on to develop post-operative vomiting (POV).

    Goal: To determine which anti-emetic--ondansetron, metoclopramide, diphenhydramine, or placebo--is most efficacious for pediatric patients in this situation.

  2. Hypothesis: Anti-emetic medications that have a different mechanism of action than the prophylactic regimen will be the most efficacious "rescue therapy."
  3. Hypothesis: Metoclopramide at the dose of 0.5 mg/kg (max dose 20 mg) will be more effective than ondansetron, diphenhydramine, or placebo as "rescue therapy."

Condition Intervention
Post Operative Nausea and Vomiting
Rescue Emetic Therapy
Drug: Metaclopramide
Drug: Ondansetron
Drug: diphenhydramine
Drug: Saline

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Rescue Emetic Therapy for Children Having Elective Therapy

Resource links provided by NLM:

Further study details as provided by Children's Hospital of Pittsburgh:

Primary Outcome Measures:
  • Primary-Incidence of POV after rescue antiemetic in PACU, car ride home, day of surgery, and POD #1 and 2 [ Time Frame: 48 hrs ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Secondary - a. Discharge times [ Time Frame: 48 hrs ] [ Designated as safety issue: Yes ]
  • Adverse events (headaches, sedation, dystonic reaction, dry mouth) [ Time Frame: 48 hrs ] [ Designated as safety issue: Yes ]
  • POV risk factors. age, personal or family history of PONV, history of motion sickness, personal or family history of smoking [ Time Frame: 48 hrs ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 1600
Study Start Date: February 2010
Estimated Study Completion Date: February 2014
Estimated Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Metoclopramide
rescue emetic therapy
Drug: Metaclopramide
0.5 mg/kg for rescue after PONV
Experimental: Ondansetron
Rescue emetic therapy
Drug: Ondansetron
0.1 mg/kg (max 4 mg0
Experimental: Diphenhydramine
Rescue emetic therapy
Drug: diphenhydramine
0.25 mg/kg (max 25 mg)
Placebo Comparator: Saline
Drug: Saline
equal volume (5 ml)as experimental rescue medications


Ages Eligible for Study:   3 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Pediatric patients 3-17 years old
  2. Patients scheduled for tonsillectomy and/or adenoidectomy (with and without myringotomy) , or dental restoration,
  3. Patients receiving a general anesthetic (inhaled agent without nitrous oxide) with POV prophylaxis with two agents (ondansetron and dexamethasone)
  4. Post operative vomiting in PACU or second stage recovery requiring antiemetic rescue.

Exclusion Criteria:

  1. Vomiting in the past 24 hours or antiemetics in previous 24 hours
  2. Allergy or sensitivity to ondansetron, dexamethasone, metoclopramide, or diphenhydramine
  3. Patients with diabetes
  4. Patients with seizures
  5. Patients receiving a benzodiazepine premedication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01067677

Contact: Franklyn P Cladis, MD 412-692-5260

United States, Pennsylvania
The Children's Hospital of Pittsburgh Recruiting
Pittsburgh, Pennsylvania, United States, 15210
Contact: Franklyn P Cladis, MD    412-692-5260   
Principal Investigator: Franklyn P Cladis, MD         
Sub-Investigator: Kathy Fertal, RN         
Sub-Investigator: Slava Martyn         
Sub-Investigator: Susan Woelfel, MD         
Sub-Investigator: Neal Campbell, MD         
Sponsors and Collaborators
Children's Hospital of Pittsburgh
Principal Investigator: Franklyn P Cladis, MD University of Pittsburgh
  More Information

No publications provided

Responsible Party: Franklyn Cladis MD, University of Pittsburgh, Department of Anesthesiology Identifier: NCT01067677     History of Changes
Other Study ID Numbers: 1-Cladis
Study First Received: February 10, 2010
Last Updated: June 21, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Children's Hospital of Pittsburgh:
Post operative nausea and vomiting
rescue emetic therapy

Additional relevant MeSH terms:
Postoperative Nausea and Vomiting
Pathologic Processes
Postoperative Complications
Signs and Symptoms
Signs and Symptoms, Digestive
Anesthetics, Local
Anti-Allergic Agents
Anti-Anxiety Agents
Antipsychotic Agents
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dermatologic Agents
Dopamine Agents
Dopamine Antagonists
Gastrointestinal Agents
Histamine Agents
Histamine Antagonists
Histamine H1 Antagonists
Hypnotics and Sedatives processed this record on November 27, 2014